SCHEMBL19946014

SCHEMBL19946014

N#CC(F)c1ccc(O)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 15/20 0.60
ESR2 Q92731 14/20 0.60
ALDH1A1 P00352 4/20 0.48
CYP3A4 P08684 3/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
CYP1A2 P05177 2/20 0.48
CYP2C9 P11712 2/20 0.48
CYP2C19 P33261 2/20 0.48
ACHE P22303 1/20 0.44
CA12 O43570 2/20 0.42
CA2 P00918 2/20 0.42
CA3 P07451 2/20 0.42
CA9 Q16790 2/20 0.42
CA14 Q9ULX7 2/20 0.42
CA6 P23280 1/20 0.42
PDCD1 Q15116 1/20 0.42
CD274 Q9NZQ7 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
LMNA P02545 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7958219 0.78 LMNA (0.47) ESR1ESR2ALDH1A1KMT2AACHE
SCHEMBL444030 0.76 TSHR (0.46) ALDH1A1CYP3A4CYP1A2CYP2C9CYP2C19
SCHEMBL27961334 0.76 CYP2A6 (0.38) ESR1ESR2ALDH1A1CYP1A2SMN1; SMN2
SCHEMBL3984010 0.76 CHRNA7 (0.44) ESR1ESR2ALDH1A1ACHESMN1; SMN2
SCHEMBL10344666 0.76 ESR1 (0.44) ESR1ESR2ALDH1A1CYP3A4MEN1
SCHEMBL10159567 0.75 TSHR (0.52) ALDH1A1SMN1; SMN2LMNAHPGD
SCHEMBL125355 0.75 ESR1 (0.65) ESR1ESR2ALDH1A1CYP3A4MEN1
SCHEMBL1323137 0.75 TSHR (0.52) ALDH1A1SMN1; SMN2LMNAHPGD
SCHEMBL22310259 0.75 ESR1 (1.00) ESR1ESR2ALDH1A1CYP3A4MEN1
SCHEMBL27702661 0.75 ESR1 (0.65) ESR1ESR2ALDH1A1CYP3A4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112028825-B Tyrosine kinase inhibitor and pharmaceutical composition containing same 广东众生睿创生物科技有限公司 2025-03-14 CN disclosed
EP-3293177-B1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GUANGDONG RAYNOVENT BIOTECH CO LTD (CN) 2024-11-27 EP disclosed
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same Guangdong Raynovent Biotech Co., Ltd. (CN) 2020-05-19 US disclosed
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Guangdong Raynovent Biotech Co., Ltd. (CN) 2019-04-25 US disclosed
EP-3293177-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2018-03-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME ABL1, LCK, ERBB2 ESR1 2044/4885ESR2 2686/4885ALDH1A1 2300/4885
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same ABL1, LCK, ERBB2 ESR1 2044/4885ESR2 2686/4885ALDH1A1 2300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.